Biomed Industries, a bio-pharmaceutical company, offered to acquire Neoleukin Therapeutics, a biotechnology company, for $68m. "We believe our offer is very compelling as it provides Neoleukin's shareholders with a highly certain and significant return and the ability to obtain liquidity for their shares, as well as the upside potential of Biomed," Lloyd L. Tran, Biomed Industries Chairman and CEO.